Skip to main content

Daily Endocrinology Research Analysis

3 papers

Three studies reshape endocrinology and metabolism this cycle: (1) mechanosensory Piezo2 signaling in sensory neurons restrains systemic hypermetabolism and controls brown/beige fat biology; (2) an epigenetic lncRNA–R-loop–TET3 axis (DSP-AS1) impairs desmoplakin transcription and re-epithelialization in diabetic wounds; and (3) a machine-learning model using longitudinal risk trajectories markedly improves 10-year cardiovascular risk prediction in type 2 diabetes.

Summary

Three studies reshape endocrinology and metabolism this cycle: (1) mechanosensory Piezo2 signaling in sensory neurons restrains systemic hypermetabolism and controls brown/beige fat biology; (2) an epigenetic lncRNA–R-loop–TET3 axis (DSP-AS1) impairs desmoplakin transcription and re-epithelialization in diabetic wounds; and (3) a machine-learning model using longitudinal risk trajectories markedly improves 10-year cardiovascular risk prediction in type 2 diabetes.

Research Themes

  • Sensory neurobiology governing energy homeostasis
  • Epigenetic regulation of diabetic wound healing
  • AI-enabled cardiovascular risk prediction in type 2 diabetes

Selected Articles

1. Piezo2 in sensory neurons regulates systemic and adipose tissue metabolism.

90Level VBasic/Mechanistic researchCell metabolism · 2025PMID: 39919739

Using multiple genetic mouse models, the authors show that mechanosensory Piezo2 in Runx3/PV sensory neurons constrains thermogenic adipose remodeling and systemic hypermetabolism. Piezo2 deletion protects against high-fat-diet obesity, improves insulin sensitivity, and induces browning/beiging, likely via increased norepinephrine.

Impact: This uncovers a previously unappreciated sensory mechanotransduction pathway controlling adipose biology and whole-body metabolism, opening targets beyond classical sympathetic circuits.

Clinical Implications: If conserved in humans, modulating Piezo2-mediated sensory signaling could complement anti-obesity and insulin-sensitizing strategies by tuning adipose tissue thermogenesis.

Key Findings

  • Targeting Runx3/PV sensory neurons yielded reduced adiposity with improved insulin sensitivity and glucose tolerance.
  • Piezo2 deletion in PV sensory neurons protected against high-fat-diet-induced obesity and induced browning/beiging of adipose tissue.
  • Findings support a model where Piezo2-sensed mechanical signals in sensory neurons restrain systemic hypermetabolism, potentially via elevated norepinephrine.

Methodological Strengths

  • Multiple independent genetic mouse models targeting Runx3/PV neurons and Piezo2 deletion.
  • Comprehensive in vivo metabolic phenotyping including adipose morphology and insulin sensitivity.

Limitations

  • Preclinical mouse data without direct human validation.
  • Mechanistic link between mechanosensation and norepinephrine dynamics requires further causal dissection.

Future Directions: Validate Piezo2-sensory neuron control of adipose thermogenesis in human tissues or models; explore pharmacologic or neuromodulatory approaches to modulate this axis safely.

2. The Diminution of R-Loops Generated by LncRNA DSP-AS1 Inhibits DSP Gene Transcription to Impede the Re-Epithelialization During Diabetic Wound Healing.

82.5Level VBasic/Mechanistic researchAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025PMID: 39921255

The study identifies an epigenetic mechanism in diabetic wounds: reduced lncRNA DSP-AS1–mediated R-loop formation at the DSP promoter diminishes TET3 recruitment and demethylation, downregulating desmoplakin and impairing keratinocyte MET and re-epithelialization.

Impact: Reveals a tractable lncRNA–R-loop–TET3 axis driving impaired re-epithelialization, suggesting novel nucleic acid or epigenetic therapies for diabetic foot ulcers.

Clinical Implications: Therapeutically augmenting DSP-AS1 function, stabilizing R-loops at the DSP promoter, or enhancing TET3 recruitment may accelerate re-epithelialization in refractory diabetic wounds.

Key Findings

  • Re-epithelialization failure in diabetic wounds is linked to impaired MET of keratinocytes rather than EMT.
  • Desmoplakin (DSP) is downregulated due to reduced TET3 occupancy and diminished TET3-dependent demethylation at the DSP promoter.
  • lncRNA DSP-AS1 forms R-loops at the DSP promoter to recruit TET3; its downregulation in diabetic skin reduces R-loops and suppresses DSP transcription.

Methodological Strengths

  • Mechanistic dissection linking promoter methylation dynamics, TET3 occupancy, and lncRNA-mediated R-loop formation.
  • In vivo diabetic models coupled with molecular assays (qRT-PCR, protein analyses, interaction assays).

Limitations

  • Predominantly preclinical with species-specific differences likely; human tissue validation scope is limited in the abstract.
  • Therapeutic modulation of R-loops/TET3 may carry off-target genomic risks requiring careful safety evaluation.

Future Directions: Validate DSP-AS1/TET3/R-loop signatures in human diabetic ulcer biopsies; develop RNA therapeutics or epigenetic modulators to restore DSP expression and MET; assess safety of R-loop targeting.

3. Predicting cardiovascular outcomes in Chinese patients with type 2 diabetes by combining risk factor trajectories and machine learning algorithm: a cohort study.

79Level IICohortCardiovascular diabetology · 2025PMID: 39920715

In 16,378 Chinese adults with type 2 diabetes, a machine-learning model using 4-year trajectories of risk factors achieved C-index 0.80 for 10-year cardiovascular events, outperforming China-PAR and PREVENT with marked NRI/IDI gains. Dynamic trajectories and ML both contributed to improved discrimination and stratification.

Impact: Demonstrates a practical, trajectory-informed ML approach that substantially outperforms established calculators, enabling personalized cardiovascular risk management in diabetes.

Clinical Implications: Incorporation of longitudinal risk trajectories into EHR-enabled ML tools could refine cardiovascular risk stratification, guide therapy intensity, and monitor risk transitions in type 2 diabetes.

Key Findings

  • ML-CVD-C achieved C-index 0.80 (95% CI 0.78–0.82) for 10-year CV outcomes, outperforming China-PAR, PREVENT, and a baseline-only ML model (C=0.62–0.65).
  • Substantial reclassification improvements versus comparators (NRI 44–58%; IDI ~8–10%), with both trajectories and ML contributing to performance.
  • All models tended to overestimate high-risk prevalence; transition analyses showed risk reductions for those remaining stable or reclassified downward.

Methodological Strengths

  • Large prospective cohort with explicit train/test split and head-to-head comparisons with established risk scores.
  • Use of longitudinal trajectories (4-year changes) rather than static baselines, improving discrimination and reclassification.

Limitations

  • Single-cohort internal validation without external validation; potential overfitting/generalizability concerns.
  • Observed overestimation of high-risk prevalence across models; calibration optimization needed before clinical deployment.

Future Directions: External validation across diverse Chinese and non-Chinese T2D populations; EHR integration trials to test clinical utility and impact on outcomes; continuous calibration updating.